ClinicalTrials.gg
CompletedNCT03180619Updated Sep 27, 2021Results posted

Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV)

A Phase 2 interventional study of TAF in Chronic Hepatitis B, sponsored by Gilead Sciences. Completed at 30 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-27.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
124
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic — 5 open to participants now, 10 under way, 1 of them phase 3. tenofovir alafenamide · Hepatitis B, Chronic.

Enrollment
13th of 26
124 · median 124
Started
2017
with 2 others
Phase 2
4 of 26
none open now
Registered
4th of 26
by date
Lead sponsor
5 of 26
Gilead Sciences

Among the 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic, this one is the 13th largest by enrollment, is one of 3 that started in 2017, is one of 4 in phase 2, and was the 4th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

5 of the 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tenofovir alafenamide

tenofovir alafenamide: first FDA approval 2015 (GENVOYA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the safety and tolerability and virologic response of tenofovir alafenamide (TAF) in virologically suppressed chronic hepatitis B participants with renal and/or hepatic impairment.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

All Participants (Parts A and B):

  • Adult male or non-pregnant female individuals
  • Documented evidence of chronic infection
  • (ALT) ≤ 10 × (ULN)

Part A Only (renal impairment):

  • Maintained on TDF and/or other OAV treatment(s) for CHB for at least 48 weeks and with viral suppression (HBV deoxyribonucleic acid [DNA] \< lower limit of quantitation [LLOQ]) for ≥ 6 months prior to screening

    • All individuals must have HBV DNA \< 20 International units per milliliter (IU/mL) at screening by central laboratory
    • Both Hepatitis B e-Antigen (HBeAg) positive and negative individuals are eligible to participate
  • Moderate renal impairment (30 milliliters per minute [mL/min] ≤ estimated by the formula [eGFRcg] ≤ 59 mL/min), severe renal impairment (15 mL/min ≤ eGFRcg \< 30 mL/min) or end stage renal disease (ESRD) (eGFR \< 15 mL/min) maintained on hemodialysis (HD)
  • Stable renal function (for participants with moderate or severe impairment): serum creatinine measured at least once within three months prior to screening. The measurement difference between the value measured within three months prior to screening versus the screening value must be ≤ 25% of the screening value

Part B Only (hepatic impairment):

  • Maintained on TDF and/or other OAV(s) for CHB for at least 48 weeks and with viral suppression (HBV DNA \< LLOQ) for ≥ 6 months prior to screening

    • All individuals must have HBV DNA \< 20 IU/mL at screening by central laboratory
    • Both HBeAg positive and negative individuals are eligible to participate
  • -turcotte (CPT) score of 7-12 (inclusive) OR a past history of CPT score ≥ 7 and any CPT score ≤ 12 at screening
  • eGFRCG ≥ 30 mL/min using the Cockcroft-Gault equation

Key Exclusion Criteria:

All Individuals (Parts A \& B):

  • Women who are breastfeeding or who believe they may wish to become pregnant during the course of the study
  • Males and females of who are unwilling to use an "effective", protocol-specified method(s) of during the study
  • Co-infection with virus (HCV), (HIV), or hepatitis D virus (HDV)
  • Prior Interferon (IFN) use within 6 months of screening
  • Evidence of hepatocellular carcinoma
  • Received solid organ or bone marrow transplant
  • Significant cardiovascular, pulmonary, or neurological disease
  • within 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection (basal cell skin cancer, etc.). Individuals under evaluation for possible malignancy are not eligible
  • Currently receiving therapy with immunomodulators (e.g. ), nephrotoxic agents, or agents capable of modifying renal excretion
  • Known to study drugs, metabolites, or formulation
  • Current alcohol or substance abuse judged by the investigator to potentially interfere with individual's compliance
  • Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the individual unsuitable for the study or unable to comply with dosing requirements.

Part A Only (Renal Impairment):

  • Current or historical evidence of clinical hepatic decompensation (e.g., ascites, encephalopathy or variceal hemorrhage)
  • Abnormal hematological and biochemical parameters, including:

    • \< 9 grams per deciliter (g/dL)
    • \< 750/cubic millimeter (mm\^3)
    • ≤ 50,000/mm\^3
    • Aspartate aminotransferase (AST) > 10 × ULN
    • Albumin \< 3.0 g/dL
    • Total > 2.5 × ULN
    • of prothrombin time (INR) > 1.5 × ULN (unless stable on anticoagulant regimen)
  • Individuals with ESRD (i.e. eGFRcg \< 15 mL/min) not on HD, or those on other forms of renal replacement therapy (i.e. peritoneal dialysis)

Part B Only (Hepatic Impairment):

  • Active variceal bleeding within 6 months or prior placement of a portosystemic shunt (such as transjugular intrahepatic portosystemic shunt [TIPS])
  • History of hepatorenal syndrome, hepatopulmonary syndrome, Grade 3 or Grade 4 hepatic encephalopathy, or spontaneous bacterial peritonitis within 6 months of screening
  • Grade 2 hepatic encephalopathy at screening
  • Model for end-stage liver disease (MELD) score ≥ 30
  • Abnormal hematological and biochemical parameters, including

    • Absolute neutrophil count \< 750/mm\^3
    • Platelets \< 30,000/mm\^3
    • Hemoglobin \< 8.0 g/dL

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    Part A (Renal Impairment): Moderate or Severe Renal Impairment

    Participants with chronic hepatitis B (CHB) and moderate or severe renal impairment who were virologically suppressed and taking tenofovir disoproxil fumarate (TDF), a TDF-containing anti-hepatitis B virus (HBV) regimen, or other oral antivirals (OAVs), will switch to tenofovir alafenamide (TAF) and receive TAF 25 milligram (mg) tablet once daily orally for 96 weeks.

    Drug: TAF

  • Experimental
    Part A (Renal Impairment): End Stage Renal Disease

    Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, will switch to TAF and receive TAF 25 mg tablet once daily orally for 96 weeks.

    Drug: TAF

  • Experimental
    Part B: Hepatic Impairment

    Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, will switch to TAF and receive TAF 25 mg tablet once daily orally for 96 weeks.

    Drug: TAF

Interventions

  • DrugTAF

    Tablet administered orally once daily

    Also known as: Vemlidy®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Virologic Response (Plasma Hepatitis B Virus [HBV] Deoxyribonucleic Acid [DNA] < 20 IU/mL) at Week 24

    The percentage of participants with HBV DNA \< 20 IU/mL at Week 24 was determined by the Missing = Failure (M = F) approach.

    Time frame: Week 24

  2. Percentage of Participants Who Experienced Graded Treatment-Emergent Adverse Events (AEs) at Week 24

    Treatment-emergent AEs were defined as: * Any AEs with an onset date on or after the study drug start date and no later than the study drug stop date + 3 days after permanent discontinuation of study drug; * Any AEs with onset date on or after the study drug start date for those who have not permanently discontinued study drug; * Any AEs leading to premature discontinuation of study drug. The most severe graded AE from all tests was counted for each participant.

    Time frame: Week 24

  3. Percentage of Participants Who Experienced Graded Treatment-Emergent Laboratory Abnormalities at Week 24

    Graded treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any postbaseline visit, up to and including the date of last dose of study drug + 3 days for participants who permanently discontinued study drug or the last available date in the database snapshot for participants who were on treatment at the time of the analysis. The most severe graded abnormality from all tests was counted for each participant.

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants Who Experienced Graded Treatment-Emergent AEs at Week 48

    Treatment-emergent AEs were defined as: Any AEs with an onset date on or after the study drug start date and no later than the study drug stop date + 3 days after permanent discontinuation of study drug; Any AEs with onset date on or after the study drug start date for those who have not permanently discontinued study drug; Any AEs leading to premature discontinuation of study drug. The most severe graded AE from all tests was counted for each participant.

    Time frame: Week 48

  2. Percentage of Participants Who Experienced Graded Treatment-Emergent AEs at Week 96

    Treatment-emergent AEs were defined as: Any AEs with an onset date on or after the study drug start date and no later than the study drug stop date + 3 days after permanent discontinuation of study drug; Any AEs with onset date on or after the study drug start date for those who have not permanently discontinued study drug; Any AEs leading to premature discontinuation of study drug. The most severe graded AE from all tests was counted for each participant.

    Time frame: Week 96

  3. Percentage of Participants Who Experienced Graded Treatment-Emergent Laboratory Abnormalities at Week 48

    Graded treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any postbaseline visit, up to and including the date of last dose of study drug + 3 days for participants who permanently discontinued study drug or the last available date in the database snapshot for participants who were on treatment at the time of the analysis. The most severe graded abnormality from all tests was counted for each participant.

    Time frame: Week 48

  4. Percentage of Participants Who Experienced Graded Treatment-Emergent Laboratory Abnormalities at Week 96

    Graded treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any post-baseline visit, up to and including the date of last dose of study drug + 3 days for participants who permanently discontinued study drug or the last available date in the database snapshot for participants who were on treatment at the time of the analysis. The most severe graded abnormality from all tests was counted for each participant.

    Time frame: Week 96

  5. Change From Baseline in Estimated Glomerular Filtration Rate by the Cockcroft-Gault Formula (eGFRcg) in Participants With Moderate or Severe Renal Impairment and Hepatically Impaired Participants at Week 24

    GFR is a measure of the rate at which blood is filtered by the kidney. Cockcroft-Gault is an equation (calculation) used to estimate GFR based on serum creatinine, weight, and gender. eGFRcg = (140 - age in years) x (body weight in kg) x (0.85 if female) divided by 72 x serum creatinine in mg/dL. Moderate renal impairment= 30 mL/min ≤ eGFRCG ≤ 59 mL/min Severe renal impairment= 15 mL/min ≤ eGFRCG \< 30 mL/min Change from baseline was calculated as the value at Week 24 minus the value at Baseline.

    Time frame: Baseline, Week 24

  6. Change From Baseline in eGFRcg in Participants With Moderate or Severe Renal Impairment and Hepatically Impaired Participants at Week 48

    GFR is a measure of the rate at which blood is filtered by the kidney. Cockcroft-Gault is an equation (calculation) used to estimate GFR based on serum creatinine, weight, and gender. eGFRcg = (140 - age in years) x (body weight in kg) x (0.85 if female) divided by 72 x serum creatinine in mg/dL. Moderate renal impairment= 30 mL/min ≤ eGFRCG ≤ 59 mL/min Severe renal impairment= 15 mL/min ≤ eGFRCG \< 30 mL/min Change from baseline was calculated as the value at Week 48 minus the value at Baseline.

    Time frame: Baseline, Week 48

  7. Change From Baseline in eGFRcg in Participants With Moderate or Severe Renal Impairment and Hepatically Impaired Participants at Week 96

    GFR is a measure of the rate at which blood is filtered by the kidney. Cockcroft-Gault is an equation (calculation) used to estimate GFR based on serum creatinine, weight, and gender. eGFRcg = (140 - age in years) x (body weight in kg) x (0.85 if female) divided by 72 x serum creatinine in mg/dL. Moderate renal impairment= 30 mL/min ≤ eGFRCG ≤ 59 mL/min Severe renal impairment= 15 mL/min ≤ eGFRCG \< 30 mL/min Change from baseline was calculated as the value at Week 96 minus the value at Baseline.

    Time frame: Baseline, Week 96

  8. Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 24

    Percent change = Change from baseline at a postbaseline visit/baseline \* 100%.

    Time frame: Baseline, Week 24

  9. Percent Change From Baseline in Hip BMD at Week 48

    Percent change = Change from baseline at a postbaseline visit/baseline \* 100%.

    Time frame: Baseline, Week 48

  10. Percent Change From Baseline in Hip BMD at Week 96

    Percent change = Change from baseline at a postbaseline visit/baseline \* 100%.

    Time frame: Baseline, Week 96

  11. Percent Change From Baseline in Spine BMD at Week 24

    Percent change = Change from baseline at a postbaseline visit/baseline \* 100%.

    Time frame: Baseline, Week 24

  12. Percent Change From Baseline in Spine BMD at Week 48

    Percent change = Change from baseline at a postbaseline visit/baseline \* 100%.

    Time frame: Baseline, Week 48

  13. Percent Change From Baseline in Spine BMD at Week 96

    Percent change = Change from baseline at a postbaseline visit/baseline \* 100%.

    Time frame: Baseline, Week 96

  14. Percentage of Participants Achieving Virologic Response (Plasma HBV DNA < 20 IU/mL) at Week 48

    The percentage of participants with HBV DNA \< 20 IU/mL at Week 48 was determined by the Missing = Failure (M = F) approach.

    Time frame: Weeks 48

  15. Percentage of Participants Achieving Virologic Response (Plasma HBV DNA < 20 IU/mL) at Week 96

    The percentage of participants with HBV DNA \< 20 IU/mL at Week 48 was determined by the Missing = Failure (M = F) approach.

    Time frame: Weeks 96

  16. Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Detected (≥ Lower Limit of Detection [LLOD]) at Week 24

    The percentage of participants with HBV DNA \< 20 IU/mL and target detected (≥ LLOD; i.e. 10 IU/mL) at Week 24 was determined by the M = F approach.

    Time frame: Week 24

  17. Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Detected (≥ LLOD) at Week 48

    The percentage of participants with HBV DNA \< 20 IU/mL and target detected (≥ LLOD; i.e. 10 IU/mL) at Week 48 was determined by the M = F approach.

    Time frame: Week 48

  18. Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Detected (≥ LLOD) at Week 96

    The percentage of participants with HBV DNA \< 20 IU/mL and target detected (≥ LLOD; i.e. 10 IU/mL) at Week 96 was determined by the M = F approach.

    Time frame: Week 96

  19. Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Not Detected (< LLOD) at Week 24

    The percentage of participants with HBV DNA \< 20 IU/mL and target not detected (\< LLOD; i.e. 10 IU/mL) at Week 24 was determined by the M = F approach.

    Time frame: Week 24

  20. Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Not Detected (< LLOD) at Week 48

    The percentage of participants with HBV DNA \< 20 IU/mL and target not detected (\< LLOD; i.e. 10 IU/mL) at Week 48 was determined by the M = F approach.

    Time frame: Weeks 48

  21. Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Not Detected (< LLOD) at Week 96

    The percentage of participants with HBV DNA \< 20 IU/mL and target not detected (\< LLOD; i.e. 10 IU/mL) at Week 96 was determined by the M = F approach.

    Time frame: Weeks 96

  22. Percentage of Participants With Serological Response: Loss of Hepatitis B s-Antigen (HBsAg) at Week 24

    HBsAg loss was defined as HBsAg changing from positive at baseline to negative at a postbaseline. The M = F approach was used for this analysis.

    Time frame: Week 24

  23. Percentage of Participants With Serological Response: Loss of HBsAg at Week 48

    HBsAg loss was defined as HBsAg changing from positive at baseline to negative at a postbaseline. The M = F approach was used for this analysis.

    Time frame: Week 48

  24. Percentage of Participants With Serological Response: Loss of HBsAg at Week 96

    HBsAg loss was defined as HBsAg changing from positive at baseline to negative at a postbaseline. The M = F approach was used for this analysis.

    Time frame: Week 96

  25. Percentage of Participants With Serological Response: Seroconversion to Anti-HBs at Week 24

    HBsAg seroconversion was defined as HBsAg loss and HBsAb test changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis.

    Time frame: Week 24

  26. Percentage of Participants With Serological Response: Seroconversion to Anti-HBs at Week 48

    HBsAg seroconversion was defined as HBsAg loss and HBsAb test changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis.

    Time frame: Week 48

  27. Percentage of Participants With Serological Response: Seroconversion to Anti-HBs at Week 96

    HBsAg seroconversion was defined as HBsAg loss and HBsAb test changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis.

    Time frame: Week 96

  28. Percentage of Participants With Serological Response: Loss of HBeAg in HBeAg-Positive Participants at Week 24

    HBeAg loss was defined as HBeAg changing from positive at baseline to negative at a postbaseline. The M = F approach was used for this analysis.

    Time frame: Week 24

  29. Percentage of Participants With Serological Response: Loss of HBeAg in HBeAg-Positive Participants at Week 48

    HBeAg loss was defined as HBeAg changing from positive at baseline to negative at a postbaseline. The M = F approach was used for this analysis.

    Time frame: Week 48

  30. Percentage of Participants With Serological Response: Loss of HBeAg in HBeAg-Positive Participants at Week 96

    HBeAg loss was defined as HBeAg changing from positive at baseline to negative at a postbaseline. The M = F approach was used for this analysis.

    Time frame: Week 96

  31. Percentage of Participants With Serological Response: Seroconversion to Anti-HBe in HBeAg-Positive Participants at Week 24

    HBeAg seroconversion was defined as HBeAg loss and HBeAb test changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis.

    Time frame: Week 24

  32. Percentage of Participants With Serological Response: Seroconversion to Anti-HBe in HBeAg-Positive Participants at Week 48

    HBeAg seroconversion was defined as HBeAg loss and HBeAb test changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis.

    Time frame: Week 48

  33. Percentage of Participants With Serological Response: Seroconversion to Anti-HBe in HBeAg-Positive Participants at Week 96

    HBeAg seroconversion was defined as HBeAg loss and HBeAb test changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis.

    Time frame: Week 96

  34. Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Week 24 by Central Laboratory and the American Association for the Study of Liver Diseases (AASLD) Criteria

    Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to \< 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to \< 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. The M = F approach was used for this analysis.

    Time frame: Week 24

  35. Percentage of Participants With Normal ALT at Week 48 by Central Laboratory and the AASLD Criteria

    Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to \< 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to \< 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. The M = F approach was used for this analysis.

    Time frame: Week 48

  36. Percentage of Participants With Normal ALT at Week 96 by Central Laboratory and the AASLD Criteria

    Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to \< 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to \< 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. The M = F approach was used for this analysis.

    Time frame: Week 96

  37. Percentage of Participants With Normalized ALT at Week 24 by Central Laboratory and the AASLD Criteria

    ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit. Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to \< 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to \< 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. The M = F approach was used for this analysis.

    Time frame: Week 24

  38. Percentage of Participants With Normalized ALT at Week 48 by Central Laboratory and the AASLD Criteria

    ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit. Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to \< 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to \< 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. The M = F approach was used for this analysis.

    Time frame: Week 48

  39. Percentage of Participants With Normalized ALT at Week 96 by Central Laboratory and the AASLD Criteria

    ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit. Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to \< 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to \< 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. The M = F approach was used for this analysis.

    Time frame: Week 96

  40. Change From Baseline in FibroTest® Score at Week 24

    The FibroTest® score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. Change from baseline was calculated as the value at Week 24 minus the value at Baseline.

    Time frame: Baseline, Week 24

  41. Change From Baseline in FibroTest® Score at Week 48

    The FibroTest® score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. Change from baseline was calculated as the value at Week 48 minus the value at Baseline.

    Time frame: Baseline, Week 48

  42. Change From Baseline in FibroTest® Score at Week 96

    The FibroTest® score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. Change from baseline was calculated as the value at Week 96 minus the value at Baseline.

    Time frame: Week 96

  43. Change From Baseline in Child-Pugh-Turcotte (CPT) Score in Hepatically Impaired Participants at Week 24

    CPT scores grade the severity of cirrhosis and are used to determine the need for liver transplantation. Scores can range from 5 to 15, with higher scores indicating a greater severity of disease.

    Time frame: Baseline, Week 24

  44. Change From Baseline in CPT Score in Hepatically Impaired Participants at Week 48

    CPT scores grade the severity of cirrhosis and are used to determine the need for liver transplantation. Scores can range from 5 to 15, with higher scores indicating a greater severity of disease.

    Time frame: Baseline, Week 48

  45. Change From Baseline in CPT Score in Hepatically Impaired Participants at Week 96

    CPT scores grade the severity of cirrhosis and are used to determine the need for liver transplantation. Scores can range from 5 to 15, with higher scores indicating a greater severity of disease.

    Time frame: Baseline, Week 96

  46. Change From Baseline in Model for End-Stage Liver Disease (MELD) Score in Hepatically Impaired Participants at Week 24

    MELD scores are used to assess prognosis and suitability for liver transplantation. Scores can range from 6 to 40, with higher scores indicating greater disease severity.

    Time frame: Baseline, Week 24

  47. Change From Baseline in MELD Score in Hepatically Impaired Participants at Week 48

    MELD scores are used to assess prognosis and suitability for liver transplantation. Scores can range from 6 to 40, with higher scores indicating greater disease severity.

    Time frame: Baseline, Week 48

  48. Change From Baseline in MELD Score in Hepatically Impaired Participants at Week 96

    MELD scores are used to assess prognosis and suitability for liver transplantation. Scores can range from 6 to 40, with higher scores indicating greater disease severity.

    Time frame: Baseline, Week 96

07

Results

Posted Apr 9, 2020

Participant flow

Participants were enrolled at study sites in Asia Pacific, North America, New Zealand and Europe. The first participant was screened on 29 June 2017. The last study visit occurred on 04 September 2020.

Participant flow — Overall Study
MilestonePart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Started781531
Completed671425
Not completed1116
Withdrew: Withdrew consent502
Withdrew: Death212
Withdrew: Adverse event201
Withdrew: Investigator's discretion201

Outcome measures

PrimaryPercentage of Participants Achieving Virologic Response (Plasma Hepatitis B Virus [HBV] Deoxyribonucleic Acid [DNA] < 20 IU/mL) at Week 24

The percentage of participants with HBV DNA \< 20 IU/mL at Week 24 was determined by the Missing = Failure (M = F) approach.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Virologic Response (Plasma Hepatitis B Virus [HBV] Deoxyribonucleic Acid [DNA] < 20 IU/mL) at Week 24
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Percentage of Participants Achieving Virologic Response (Plasma Hepatitis B Virus [HBV] Deoxyribonucleic Acid [DNA] < 20 IU/mL) at Week 2497.4100.0100.0
PrimaryPercentage of Participants Who Experienced Graded Treatment-Emergent Adverse Events (AEs) at Week 24

Treatment-emergent AEs were defined as: * Any AEs with an onset date on or after the study drug start date and no later than the study drug stop date + 3 days after permanent discontinuation of study drug; * Any AEs with onset date on or after the study drug start date for those who have not permanently discontinued study drug; * Any AEs leading to premature discontinuation of study drug. The most severe graded AE from all tests was counted for each participant.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Graded Treatment-Emergent Adverse Events (AEs) at Week 24
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Any Treatment-emergent AEs53.873.354.8
Grade 3 and Above Treatment-emergent AEs6.413.36.5
PrimaryPercentage of Participants Who Experienced Graded Treatment-Emergent Laboratory Abnormalities at Week 24

Graded treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any postbaseline visit, up to and including the date of last dose of study drug + 3 days for participants who permanently discontinued study drug or the last available date in the database snapshot for participants who were on treatment at the time of the analysis. The most severe graded abnormality from all tests was counted for each participant.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Graded Treatment-Emergent Laboratory Abnormalities at Week 24
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Any Graded Laboratory Abnormality96.2100.090.3
Grade 3 and Above Laboratory Abnormality11.546.748.4
SecondaryPercentage of Participants Who Experienced Graded Treatment-Emergent AEs at Week 48

Treatment-emergent AEs were defined as: Any AEs with an onset date on or after the study drug start date and no later than the study drug stop date + 3 days after permanent discontinuation of study drug; Any AEs with onset date on or after the study drug start date for those who have not permanently discontinued study drug; Any AEs leading to premature discontinuation of study drug. The most severe graded AE from all tests was counted for each participant.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Graded Treatment-Emergent AEs at Week 48
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Any Treatment-emergent AE71.886.771.0
Grade 3 and Above Treatment-emergent AEs15.420.012.9
SecondaryPercentage of Participants Who Experienced Graded Treatment-Emergent AEs at Week 96

Treatment-emergent AEs were defined as: Any AEs with an onset date on or after the study drug start date and no later than the study drug stop date + 3 days after permanent discontinuation of study drug; Any AEs with onset date on or after the study drug start date for those who have not permanently discontinued study drug; Any AEs leading to premature discontinuation of study drug. The most severe graded AE from all tests was counted for each participant.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Graded Treatment-Emergent AEs at Week 96
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Any Treatment-emergent AEs74.4100.077.4
Grade 3 and Above treatment-emergent AEs17.926.725.8
SecondaryPercentage of Participants Who Experienced Graded Treatment-Emergent Laboratory Abnormalities at Week 48

Graded treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any postbaseline visit, up to and including the date of last dose of study drug + 3 days for participants who permanently discontinued study drug or the last available date in the database snapshot for participants who were on treatment at the time of the analysis. The most severe graded abnormality from all tests was counted for each participant.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Graded Treatment-Emergent Laboratory Abnormalities at Week 48
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Any Graded Laboratory Abnormality96.2100.090.3
Grade 312.840.041.9
Grade 4026.79.7
SecondaryPercentage of Participants Who Experienced Graded Treatment-Emergent Laboratory Abnormalities at Week 96

Graded treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any post-baseline visit, up to and including the date of last dose of study drug + 3 days for participants who permanently discontinued study drug or the last available date in the database snapshot for participants who were on treatment at the time of the analysis. The most severe graded abnormality from all tests was counted for each participant.

Time frame:
Week 96
Reported as:
Number · percentage of particpants
Percentage of Participants Who Experienced Graded Treatment-Emergent Laboratory Abnormalities at Week 96
percentage of particpantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Any Graded Laboratory Abnormality96.2100.0100.0
Grade 315.446.741.9
Grade 41.326.712.9
SecondaryChange From Baseline in Estimated Glomerular Filtration Rate by the Cockcroft-Gault Formula (eGFRcg) in Participants With Moderate or Severe Renal Impairment and Hepatically Impaired Participants at Week 24

GFR is a measure of the rate at which blood is filtered by the kidney. Cockcroft-Gault is an equation (calculation) used to estimate GFR based on serum creatinine, weight, and gender. eGFRcg = (140 - age in years) x (body weight in kg) x (0.85 if female) divided by 72 x serum creatinine in mg/dL. Moderate renal impairment= 30 mL/min ≤ eGFRCG ≤ 59 mL/min Severe renal impairment= 15 mL/min ≤ eGFRCG \< 30 mL/min Change from baseline was calculated as the value at Week 24 minus the value at Baseline.

Time frame:
Baseline, Week 24
Reported as:
Median · mL/min
Change From Baseline in Estimated Glomerular Filtration Rate by the Cockcroft-Gault Formula (eGFRcg) in Participants With Moderate or Severe Renal Impairment and Hepatically Impaired Participants at Week 24
mL/minPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart B: Hepatic Impairment
Change From Baseline in Estimated Glomerular Filtration Rate by the Cockcroft-Gault Formula (eGFRcg) in Participants With Moderate or Severe Renal Impairment and Hepatically Impaired Participants at Week 24-0.4 (-3.9 to 4.5)1.9 (-5.6 to 12.2)
SecondaryChange From Baseline in eGFRcg in Participants With Moderate or Severe Renal Impairment and Hepatically Impaired Participants at Week 48

GFR is a measure of the rate at which blood is filtered by the kidney. Cockcroft-Gault is an equation (calculation) used to estimate GFR based on serum creatinine, weight, and gender. eGFRcg = (140 - age in years) x (body weight in kg) x (0.85 if female) divided by 72 x serum creatinine in mg/dL. Moderate renal impairment= 30 mL/min ≤ eGFRCG ≤ 59 mL/min Severe renal impairment= 15 mL/min ≤ eGFRCG \< 30 mL/min Change from baseline was calculated as the value at Week 48 minus the value at Baseline.

Time frame:
Baseline, Week 48
Reported as:
Median · mL/min
Change From Baseline in eGFRcg in Participants With Moderate or Severe Renal Impairment and Hepatically Impaired Participants at Week 48
mL/minPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart B: Hepatic Impairment
Change From Baseline in eGFRcg in Participants With Moderate or Severe Renal Impairment and Hepatically Impaired Participants at Week 48-0.5 (-4.1 to 3.0)1.2 (-13.5 to 6.5)
SecondaryChange From Baseline in eGFRcg in Participants With Moderate or Severe Renal Impairment and Hepatically Impaired Participants at Week 96

GFR is a measure of the rate at which blood is filtered by the kidney. Cockcroft-Gault is an equation (calculation) used to estimate GFR based on serum creatinine, weight, and gender. eGFRcg = (140 - age in years) x (body weight in kg) x (0.85 if female) divided by 72 x serum creatinine in mg/dL. Moderate renal impairment= 30 mL/min ≤ eGFRCG ≤ 59 mL/min Severe renal impairment= 15 mL/min ≤ eGFRCG \< 30 mL/min Change from baseline was calculated as the value at Week 96 minus the value at Baseline.

Time frame:
Baseline, Week 96
Reported as:
Median · mL/min
Change From Baseline in eGFRcg in Participants With Moderate or Severe Renal Impairment and Hepatically Impaired Participants at Week 96
mL/minPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart B: Hepatic Impairment
Change From Baseline in eGFRcg in Participants With Moderate or Severe Renal Impairment and Hepatically Impaired Participants at Week 961.0 (-2.8 to 4.5)-2.4 (-11.4 to 10.7)
SecondaryPercent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 24

Percent change = Change from baseline at a postbaseline visit/baseline \* 100%.

Time frame:
Baseline, Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 24
percent changePart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 240.135 ± 1.83480.322 ± 2.18350.322 ± 2.5105
SecondaryPercent Change From Baseline in Hip BMD at Week 48

Percent change = Change from baseline at a postbaseline visit/baseline \* 100%.

Time frame:
Baseline, Week 48
Reported as:
Mean · percent change
Percent Change From Baseline in Hip BMD at Week 48
percent changePart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Percent Change From Baseline in Hip BMD at Week 480.565 ± 2.6160-1.075 ± 3.6355-0.221 ± 3.0158
SecondaryPercent Change From Baseline in Hip BMD at Week 96

Percent change = Change from baseline at a postbaseline visit/baseline \* 100%.

Time frame:
Baseline, Week 96
Reported as:
Mean · percent change
Percent Change From Baseline in Hip BMD at Week 96
percent changePart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Percent Change From Baseline in Hip BMD at Week 960.425 ± 2.8381-0.834 ± 4.71710.277 ± 3.2549
SecondaryPercent Change From Baseline in Spine BMD at Week 24

Percent change = Change from baseline at a postbaseline visit/baseline \* 100%.

Time frame:
Baseline, Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Spine BMD at Week 24
percent changePart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Percent Change From Baseline in Spine BMD at Week 241.229 ± 3.42520.683 ± 3.13701.258 ± 2.3416
SecondaryPercent Change From Baseline in Spine BMD at Week 48

Percent change = Change from baseline at a postbaseline visit/baseline \* 100%.

Time frame:
Baseline, Week 48
Reported as:
Mean · percent change
Percent Change From Baseline in Spine BMD at Week 48
percent changePart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Percent Change From Baseline in Spine BMD at Week 481.516 ± 3.74860.016 ± 4.16360.535 ± 3.4386
SecondaryPercent Change From Baseline in Spine BMD at Week 96

Percent change = Change from baseline at a postbaseline visit/baseline \* 100%.

Time frame:
Baseline, Week 96
Reported as:
Mean · percent change
Percent Change From Baseline in Spine BMD at Week 96
percent changePart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Percent Change From Baseline in Spine BMD at Week 961.293 ± 4.4136-0.283 ± 4.5327-0.249 ± 3.9127
SecondaryPercentage of Participants Achieving Virologic Response (Plasma HBV DNA < 20 IU/mL) at Week 48

The percentage of participants with HBV DNA \< 20 IU/mL at Week 48 was determined by the Missing = Failure (M = F) approach.

Time frame:
Weeks 48
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Virologic Response (Plasma HBV DNA < 20 IU/mL) at Week 48
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Percentage of Participants Achieving Virologic Response (Plasma HBV DNA < 20 IU/mL) at Week 4892.393.3100.0
SecondaryPercentage of Participants Achieving Virologic Response (Plasma HBV DNA < 20 IU/mL) at Week 96

The percentage of participants with HBV DNA \< 20 IU/mL at Week 48 was determined by the Missing = Failure (M = F) approach.

Time frame:
Weeks 96
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Virologic Response (Plasma HBV DNA < 20 IU/mL) at Week 96
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Percentage of Participants Achieving Virologic Response (Plasma HBV DNA < 20 IU/mL) at Week 9683.386.777.4
SecondaryPercentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Detected (≥ Lower Limit of Detection [LLOD]) at Week 24

The percentage of participants with HBV DNA \< 20 IU/mL and target detected (≥ LLOD; i.e. 10 IU/mL) at Week 24 was determined by the M = F approach.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Detected (≥ Lower Limit of Detection [LLOD]) at Week 24
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Detected (≥ Lower Limit of Detection [LLOD]) at Week 2421.840.022.6
SecondaryPercentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Detected (≥ LLOD) at Week 48

The percentage of participants with HBV DNA \< 20 IU/mL and target detected (≥ LLOD; i.e. 10 IU/mL) at Week 48 was determined by the M = F approach.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Detected (≥ LLOD) at Week 48
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Detected (≥ LLOD) at Week 4826.926.725.8
SecondaryPercentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Detected (≥ LLOD) at Week 96

The percentage of participants with HBV DNA \< 20 IU/mL and target detected (≥ LLOD; i.e. 10 IU/mL) at Week 96 was determined by the M = F approach.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Detected (≥ LLOD) at Week 96
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Detected (≥ LLOD) at Week 9614.120.00
SecondaryPercentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Not Detected (< LLOD) at Week 24

The percentage of participants with HBV DNA \< 20 IU/mL and target not detected (\< LLOD; i.e. 10 IU/mL) at Week 24 was determined by the M = F approach.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Not Detected (< LLOD) at Week 24
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Not Detected (< LLOD) at Week 2475.660.077.4
SecondaryPercentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Not Detected (< LLOD) at Week 48

The percentage of participants with HBV DNA \< 20 IU/mL and target not detected (\< LLOD; i.e. 10 IU/mL) at Week 48 was determined by the M = F approach.

Time frame:
Weeks 48
Reported as:
Number · percentage of participants
Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Not Detected (< LLOD) at Week 48
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Not Detected (< LLOD) at Week 4865.466.774.2
SecondaryPercentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Not Detected (< LLOD) at Week 96

The percentage of participants with HBV DNA \< 20 IU/mL and target not detected (\< LLOD; i.e. 10 IU/mL) at Week 96 was determined by the M = F approach.

Time frame:
Weeks 96
Reported as:
Number · percentage of participants
Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Not Detected (< LLOD) at Week 96
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Not Detected (< LLOD) at Week 9669.266.777.4
SecondaryPercentage of Participants With Serological Response: Loss of Hepatitis B s-Antigen (HBsAg) at Week 24

HBsAg loss was defined as HBsAg changing from positive at baseline to negative at a postbaseline. The M = F approach was used for this analysis.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Serological Response: Loss of Hepatitis B s-Antigen (HBsAg) at Week 24
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Percentage of Participants With Serological Response: Loss of Hepatitis B s-Antigen (HBsAg) at Week 24000
SecondaryPercentage of Participants With Serological Response: Loss of HBsAg at Week 48

HBsAg loss was defined as HBsAg changing from positive at baseline to negative at a postbaseline. The M = F approach was used for this analysis.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Serological Response: Loss of HBsAg at Week 48
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Percentage of Participants With Serological Response: Loss of HBsAg at Week 480.06.73.3
SecondaryPercentage of Participants With Serological Response: Loss of HBsAg at Week 96

HBsAg loss was defined as HBsAg changing from positive at baseline to negative at a postbaseline. The M = F approach was used for this analysis.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With Serological Response: Loss of HBsAg at Week 96
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Percentage of Participants With Serological Response: Loss of HBsAg at Week 96006.7
SecondaryPercentage of Participants With Serological Response: Seroconversion to Anti-HBs at Week 24

HBsAg seroconversion was defined as HBsAg loss and HBsAb test changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Serological Response: Seroconversion to Anti-HBs at Week 24
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Percentage of Participants With Serological Response: Seroconversion to Anti-HBs at Week 24000
SecondaryPercentage of Participants With Serological Response: Seroconversion to Anti-HBs at Week 48

HBsAg seroconversion was defined as HBsAg loss and HBsAb test changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Serological Response: Seroconversion to Anti-HBs at Week 48
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Percentage of Participants With Serological Response: Seroconversion to Anti-HBs at Week 48000
SecondaryPercentage of Participants With Serological Response: Seroconversion to Anti-HBs at Week 96

HBsAg seroconversion was defined as HBsAg loss and HBsAb test changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With Serological Response: Seroconversion to Anti-HBs at Week 96
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Percentage of Participants With Serological Response: Seroconversion to Anti-HBs at Week 96000
SecondaryPercentage of Participants With Serological Response: Loss of HBeAg in HBeAg-Positive Participants at Week 24

HBeAg loss was defined as HBeAg changing from positive at baseline to negative at a postbaseline. The M = F approach was used for this analysis.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Serological Response: Loss of HBeAg in HBeAg-Positive Participants at Week 24
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Percentage of Participants With Serological Response: Loss of HBeAg in HBeAg-Positive Participants at Week 24000
SecondaryPercentage of Participants With Serological Response: Loss of HBeAg in HBeAg-Positive Participants at Week 48

HBeAg loss was defined as HBeAg changing from positive at baseline to negative at a postbaseline. The M = F approach was used for this analysis.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Serological Response: Loss of HBeAg in HBeAg-Positive Participants at Week 48
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Percentage of Participants With Serological Response: Loss of HBeAg in HBeAg-Positive Participants at Week 48000
SecondaryPercentage of Participants With Serological Response: Loss of HBeAg in HBeAg-Positive Participants at Week 96

HBeAg loss was defined as HBeAg changing from positive at baseline to negative at a postbaseline. The M = F approach was used for this analysis.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With Serological Response: Loss of HBeAg in HBeAg-Positive Participants at Week 96
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Percentage of Participants With Serological Response: Loss of HBeAg in HBeAg-Positive Participants at Week 96033.30
SecondaryPercentage of Participants With Serological Response: Seroconversion to Anti-HBe in HBeAg-Positive Participants at Week 24

HBeAg seroconversion was defined as HBeAg loss and HBeAb test changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Serological Response: Seroconversion to Anti-HBe in HBeAg-Positive Participants at Week 24
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Percentage of Participants With Serological Response: Seroconversion to Anti-HBe in HBeAg-Positive Participants at Week 24000
SecondaryPercentage of Participants With Serological Response: Seroconversion to Anti-HBe in HBeAg-Positive Participants at Week 48

HBeAg seroconversion was defined as HBeAg loss and HBeAb test changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Serological Response: Seroconversion to Anti-HBe in HBeAg-Positive Participants at Week 48
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Percentage of Participants With Serological Response: Seroconversion to Anti-HBe in HBeAg-Positive Participants at Week 48000
SecondaryPercentage of Participants With Serological Response: Seroconversion to Anti-HBe in HBeAg-Positive Participants at Week 96

HBeAg seroconversion was defined as HBeAg loss and HBeAb test changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With Serological Response: Seroconversion to Anti-HBe in HBeAg-Positive Participants at Week 96
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Percentage of Participants With Serological Response: Seroconversion to Anti-HBe in HBeAg-Positive Participants at Week 96033.30
SecondaryPercentage of Participants With Normal Alanine Aminotransferase (ALT) at Week 24 by Central Laboratory and the American Association for the Study of Liver Diseases (AASLD) Criteria

Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to \< 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to \< 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. The M = F approach was used for this analysis.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Week 24 by Central Laboratory and the American Association for the Study of Liver Diseases (AASLD) Criteria
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
ALT by central laboratory92.393.383.9
ALT by AASLD criteria87.293.380.6
SecondaryPercentage of Participants With Normal ALT at Week 48 by Central Laboratory and the AASLD Criteria

Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to \< 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to \< 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. The M = F approach was used for this analysis.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Normal ALT at Week 48 by Central Laboratory and the AASLD Criteria
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
ALT by central laboratory89.786.790.3
ALT by AASLD criteria87.280.080.6
SecondaryPercentage of Participants With Normal ALT at Week 96 by Central Laboratory and the AASLD Criteria

Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to \< 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to \< 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. The M = F approach was used for this analysis.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With Normal ALT at Week 96 by Central Laboratory and the AASLD Criteria
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
ALT by central laboratory82.186.771.0
ALT by AASLD criteria74.486.758.1
SecondaryPercentage of Participants With Normalized ALT at Week 24 by Central Laboratory and the AASLD Criteria

ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit. Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to \< 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to \< 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. The M = F approach was used for this analysis.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Normalized ALT at Week 24 by Central Laboratory and the AASLD Criteria
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Normalized ALT by Central Laboratory66.7—50.0
Normalized ALT by AASLD Criteria40.0—60.0
SecondaryPercentage of Participants With Normalized ALT at Week 48 by Central Laboratory and the AASLD Criteria

ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit. Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to \< 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to \< 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. The M = F approach was used for this analysis.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Normalized ALT at Week 48 by Central Laboratory and the AASLD Criteria
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Normalized ALT by Central Laboratory33.3—75.0
Normalized ALT by AASLD Criteria60.0—60.0
SecondaryPercentage of Participants With Normalized ALT at Week 96 by Central Laboratory and the AASLD Criteria

ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit. Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to \< 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to \< 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. The M = F approach was used for this analysis.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With Normalized ALT at Week 96 by Central Laboratory and the AASLD Criteria
percentage of participantsPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Normalized ALT by Central Laboratory33.3—50.0
Normalized ALT by AASLD Criteria20.0—50.0
SecondaryChange From Baseline in FibroTest® Score at Week 24

The FibroTest® score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. Change from baseline was calculated as the value at Week 24 minus the value at Baseline.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in FibroTest® Score at Week 24
units on a scalePart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Change From Baseline in FibroTest® Score at Week 24-0.01 ± 0.099-0.01 ± 0.064-0.05 ± 0.106
SecondaryChange From Baseline in FibroTest® Score at Week 48

The FibroTest® score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. Change from baseline was calculated as the value at Week 48 minus the value at Baseline.

Time frame:
Baseline, Week 48
Reported as:
Mean · units on a scale
Change From Baseline in FibroTest® Score at Week 48
units on a scalePart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Change From Baseline in FibroTest® Score at Week 48-0.03 ± 0.102-0.01 ± 0.071-0.03 ± 0.102
SecondaryChange From Baseline in FibroTest® Score at Week 96

The FibroTest® score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. Change from baseline was calculated as the value at Week 96 minus the value at Baseline.

Time frame:
Week 96
Reported as:
Mean · units on a scale
Change From Baseline in FibroTest® Score at Week 96
units on a scalePart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic Impairment
Change From Baseline in FibroTest® Score at Week 96-0.01 ± 0.1140.03 ± 0.107-0.02 ± 0.118
SecondaryChange From Baseline in Child-Pugh-Turcotte (CPT) Score in Hepatically Impaired Participants at Week 24

CPT scores grade the severity of cirrhosis and are used to determine the need for liver transplantation. Scores can range from 5 to 15, with higher scores indicating a greater severity of disease.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in Child-Pugh-Turcotte (CPT) Score in Hepatically Impaired Participants at Week 24
units on a scalePart B: Hepatic Impairment
Change From Baseline in Child-Pugh-Turcotte (CPT) Score in Hepatically Impaired Participants at Week 240 ± 1.1
SecondaryChange From Baseline in CPT Score in Hepatically Impaired Participants at Week 48

CPT scores grade the severity of cirrhosis and are used to determine the need for liver transplantation. Scores can range from 5 to 15, with higher scores indicating a greater severity of disease.

Time frame:
Baseline, Week 48
Reported as:
Mean · units on a scale
Change From Baseline in CPT Score in Hepatically Impaired Participants at Week 48
units on a scalePart B: Hepatic Impairment
Change From Baseline in CPT Score in Hepatically Impaired Participants at Week 480 ± 1.1
SecondaryChange From Baseline in CPT Score in Hepatically Impaired Participants at Week 96

CPT scores grade the severity of cirrhosis and are used to determine the need for liver transplantation. Scores can range from 5 to 15, with higher scores indicating a greater severity of disease.

Time frame:
Baseline, Week 96
Reported as:
Mean · units on a scale
Change From Baseline in CPT Score in Hepatically Impaired Participants at Week 96
units on a scalePart B: Hepatic Impairment
Change From Baseline in CPT Score in Hepatically Impaired Participants at Week 960 ± 1.2
SecondaryChange From Baseline in Model for End-Stage Liver Disease (MELD) Score in Hepatically Impaired Participants at Week 24

MELD scores are used to assess prognosis and suitability for liver transplantation. Scores can range from 6 to 40, with higher scores indicating greater disease severity.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in Model for End-Stage Liver Disease (MELD) Score in Hepatically Impaired Participants at Week 24
units on a scalePart B: Hepatic Impairment
Change From Baseline in Model for End-Stage Liver Disease (MELD) Score in Hepatically Impaired Participants at Week 24-0.6 ± 1.94
SecondaryChange From Baseline in MELD Score in Hepatically Impaired Participants at Week 48

MELD scores are used to assess prognosis and suitability for liver transplantation. Scores can range from 6 to 40, with higher scores indicating greater disease severity.

Time frame:
Baseline, Week 48
Reported as:
Mean · units on a scale
Change From Baseline in MELD Score in Hepatically Impaired Participants at Week 48
units on a scalePart B: Hepatic Impairment
Change From Baseline in MELD Score in Hepatically Impaired Participants at Week 480.1 ± 2.35
SecondaryChange From Baseline in MELD Score in Hepatically Impaired Participants at Week 96

MELD scores are used to assess prognosis and suitability for liver transplantation. Scores can range from 6 to 40, with higher scores indicating greater disease severity.

Time frame:
Baseline, Week 96
Reported as:
Mean · units on a scale
Change From Baseline in MELD Score in Hepatically Impaired Participants at Week 96
units on a scalePart B: Hepatic Impairment
Change From Baseline in MELD Score in Hepatically Impaired Participants at Week 96-1.0 ± 1.61

Adverse events

Collected over Adverse Events: From the first dose date up to last dose date (maximum: 108.1 weeks) plus 3 days; All-Cause Mortality: Enrollment up to last dose date (maximum: 166.2 weeks) plus 3 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A (Renal Impairment): Moderate or Severe Renal Impairment2/78 (2.6%)12/78 (15.4%)34/78 (43.6%)
Part A (Renal Impairment): End Stage Renal Disease (Cohort 2)1/15 (6.7%)8/15 (53.3%)15/15 (100%)
Part B (Hepatic Impairment): Moderate or Severe Hepatic Impair2/31 (6.5%)10/31 (32.3%)23/31 (74.2%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal Disease (Cohort 2)Part B (Hepatic Impairment): Moderate or Severe Hepatic Impair
Pleural effusionRespiratory, thoracic and mediastinal disorders0/782/150/31
AnaemiaBlood and lymphatic system disorders0/781/150/31
ThrombocytopeniaBlood and lymphatic system disorders0/781/150/31
Deafness neurosensoryEar and labyrinth disorders0/781/150/31
Abdominal painGastrointestinal disorders0/781/150/31
ColitisGastrointestinal disorders0/781/150/31
Intestinal obstructionGastrointestinal disorders0/781/150/31
Catheter site dischargeGeneral disorders0/781/150/31
BacteraemiaInfections and infestations0/781/150/31
Lower respiratory tract infectionInfections and infestations0/781/150/31
Most frequent other events
Showing 10 of 97
Most frequent other events
EventPart A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal Disease (Cohort 2)Part B (Hepatic Impairment): Moderate or Severe Hepatic Impair
ConstipationGastrointestinal disorders2/784/153/31
HypertensionVascular disorders2/784/151/31
AnaemiaBlood and lymphatic system disorders2/783/151/31
DiarrhoeaGastrointestinal disorders3/783/156/31
PyrexiaGeneral disorders0/783/155/31
Upper respiratory tract infectionInfections and infestations11/783/156/31
Musculoskeletal painMusculoskeletal and connective tissue disorders1/783/151/31
Pleural effusionRespiratory, thoracic and mediastinal disorders0/783/152/31
CoughRespiratory, thoracic and mediastinal disorders4/780/156/31
Bone density decreasedInvestigations1/780/155/31

Baseline characteristics

The Safety Analysis Set included all participants who were enrolled and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Part A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic ImpairmentTotal
Mean66 ± 10.154 ± 12.855 ± 10.861 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)Part A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic ImpairmentTotal
Female2131034
Male57122190
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic ImpairmentTotal
Ethnicity — Hispanic or Latino0011
Ethnicity — Not Hispanic or Latino781530123
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic ImpairmentTotal
Race — Asian59132597
Race — Black or African American3014
Race — Native Hawaiian or Pacific Islander0202
Race — White150419
Race — Other1012
Region of Enrollment
Region of Enrollment(Participants)Part A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic ImpairmentTotal
New Zealand0202
Canada220325
South Korea123520
Hong Kong141217
United States30710
Taiwan1391133
Italy130215
United Kingdom1012
Alanine Aminotransferase (ALT)
Alanine Aminotransferase (ALT)(Units/Liter (U/L))Part A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic ImpairmentTotal
Mean20 ± 9.614 ± 5.228 ± 12.421 ± 10.8
ALT Level Based on Central Lab Normal Range
ALT Level Based on Central Lab Normal Range(Participants)Part A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic ImpairmentTotal
≤ ULN751527117
> ULN - 5xULN3047
> 5xULN0000
ALT Level Based on 2018 American Association for the Study of Liver Diseases (AASLD) Normal Range
ALT Level Based on 2018 American Association for the Study of Liver Diseases (AASLD) Normal Range(Participants)Part A (Renal Impairment): Moderate or Severe Renal ImpairmentPart A (Renal Impairment): End Stage Renal DiseasePart B: Hepatic ImpairmentTotal
≤ ULN731521109
> ULN - 5xULN501015
> 5xULN0000

9 further baseline measures are reported on the registry.

08

Study locations

30 sites
  • Coalition of Inclusive Medicine
    Los Angeles, California 90020, United States
  • Silicon Valley Research Institute, Inc
    San Jose, California 95128, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Harborview Medical Center
    Seattle, Washington 98104, United States
  • University of Calgary Liver Unit
    Calgary, T2N4Z6, Canada
  • Centre de Recherche du Centre Hospitalier de l'Universite de Montreal
    Montreal, H2X 0A9, Canada
  • University Health Network,Toronto general Hospital,Toronto centre for liver disease
    Toronto, M5G 2C4, Canada
  • Toronto Liver Centre
    Toronto, M6H 3M1, Canada
  • (G.I.R.I.) GI Research Institute
    Vancouver, V6Z 2K5, Canada
  • Prince of Wales Hospital
    Shatin, NT, Hong Kong
  • Princess Margaret Hospital
    Kowloon, Hong Kong
  • Alice Ho Miu Ling Nethersole Hospital
    Tai Po, Hong Kong
  • U.O. Medicina Generale Epatologia IRCCS Humanitas Centro di Ricerca Traslazionale in Epatologia
    Rozzano, Milan 20089, Italy
  • Dipartimento di Scienze Mediche e Chirurgiche (DIMEC) AOU Policlinico S.Orsola-Malpighi di Bologna
    Bologna, 40138, Italy
  • UOC Gastroenterol-Epatol.-Fondazione IRCCS Ca Granda
    Milan, 20122, Italy
  • Dong-A University Hospital
    Busan, 49201, Korea, Republic of
  • Pusan National University Hospital
    Busan, 49241, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Yonsei University Health System, Severance Hospital
    Seoul, 120-752, Korea, Republic of
  • Auckland Clinical Studies
    Grafton, Auckland 1010, New Zealand
  • Changhua Christian Hospital
    Changhua, 500, Taiwan
  • Ditmanson Medical Foundation Chia-Yi Christian Hospital
    Chiayi City, 60002, Taiwan
  • Kaohsiung Chang Gung Memorial Hospital
    Kaohsiung City, 83301, Taiwan
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung, 807, Taiwan
  • Taichung Veterans Genl Hosp
    Taichung, 40705, Taiwan
  • National Taiwan University Hospital
    Taipei, 10001, Taiwan
  • Veterans General Hospital-Taipei
    Taipei, 11217, Taiwan
  • Chang Gung Medical Foundation, Linkou Chang Gung Memorial Hospital
    Taoyuan City, 333, Taiwan
  • Nottingham University Hospital
    London, NG7 2UH, United Kingdom
  • King's College Hospital NHS Foundation Trust
    London, SE5 9RS, United Kingdom
09

References and documents

Publications

  • Lim YS, Lin CY, Heo J, Bae H, Chuang WL, Hui AJ, et al. Safety and Efficacy of Switching to Tenofovir Alafenamide in Virally Suppressed Chronic Hepatitis B Patients With Hepatic Impairment: Week-48 Results From a Phase 2 Open-label Study [Poster SAT442]. The Digital International Liver Congress (ILC); 2020 27-29 August.
  • Janssen HLA, Lampertico P, Chen CY, Heo J, Fournier C, Ahn SH, et al. Safety and Efficacy of Switching to Tenofovir Alafenamide in Virally Suppressed Chronic Hepatitis B Patients With Renal Impairment: Week-48 Results From a Phase 2 Open-label Study [Poster SAT429]. The Digital International Liver Congress (ILC); 2020 27-29 August.
  • Lim YS, Lampertico P, Bae H, Chuang WL, Heo J, Huang YH, et al. Switching From Tenofovir Disoproxil Fumarate or Other Oral Antiviral Therapy to Tenofovir Alafenamide in Virally Suppressed Chronic Hepatitis B Patients With Hepatic Impairment: Week 24 Efficacy and Safety Results From a Phase 2 Open-label Study [Poster 501]. AASLD: The Liver Meeting; 2019 08-12 November; Boston, MA.
  • Janssen HLA, Lim YS, Gane EJ, Fournier C, Ahn SH, Tsang O, et al. Efficacy and Safety of Switching to Tenofovir Alafenamide in Virally Suppressed Chronic Hepatitis B Patients With Renal Impairment: Week 24 Results From a Phase 2 Open-label Study [Poster 483]. AASLD: The Liver Meeting; 2019 08-12 November; Boston, MA.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Mar 2019, 20 months.

Results were first posted in Apr 2020, 1 year after primary completion.

Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's 20 months is close to that.

Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2017
First posted
Jun 8, 2017
StartActual
Jun 29, 2017
Primary completionActual
Mar 27, 2019
CompletionActual
Sep 4, 2020
Results first posted
Apr 9, 2020
Last update
Sep 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03180619
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jun 8, 2017
Start date
Jun 29, 2017
Primary completion
Mar 27, 2019
Completion
Sep 4, 2020
Results posted
Apr 9, 2020
Last update
Sep 27, 2021

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir alafenamide

Start the discussion